Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

Friedrich Stölzel, MD, Michael Kramer, Brigitte Mohr, PhD, Martin Wermke, MD, Martin Bornhäuser, MD, Gerhard Ehninger, Markus Schaich, MD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 1715.

https://doi.org/10.1182/blood.V120.21.1715.1715

Published: 2012

Journal Articles

Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Stefani Parmentier, MD, Michael Kramer, Katharina Koch, Brigitte Mohr, PhD, Christian Klesse, Christian Thiede, Christoph Röllig, Mathias Hänel, MD, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, Walter E. Aulitzky, Wolfgang E. Berdel, MD, Hubert Serve, Prof. Dr. med., Stefan W. Krause, Jiri Mayer, MD, Martin Bornhäuser, MD, Gerhard Ehninger, Markus Schaich, MD

Blood (2012) 120 (21): 1481.

https://doi.org/10.1182/blood.V120.21.1481.1481

Published: 2012

Journal Articles

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

Friedrich Stölzel, MD, David M. Poitz, PhD, Laleh S. Arabanian, Jens Friedrichs, PhD, Denitsa Docheva, PhD, Matthias Schieker, MD, Fernando A. Fierro, PhD, Uwe Platzbecker, MD, Ruth H. Strasser, MD, Martin Bornhäuser, MD, Carsten Werner, PhD, Gerhard Ehninger, Thomas Illmer, MD

Blood (2012) 120 (21): 3459.

https://doi.org/10.1182/blood.V120.21.3459.3459

Published: 2012

Journal Articles

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Jan Moritz Middeke, MD, Stefani Parmentier, MD, Nael Alakel, MD, Markus Schaich, MD, Christian Thiede, Uwe Platzbecker, MD, Christoph Röllig, Mathias Hänel, MD, Gernot Stuhler, MD, Anke Morgner, MD, Uta Eulenstein, Gerhard Ehninger, Martin Bornhäuser, MD, Johannes Schetelig, MD

Blood (2012) 120 (21): 2017.

https://doi.org/10.1182/blood.V120.21.2017.2017

Published: 2012

Journal Articles

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Sebastian Tuve, MD, Felix Bahr, Rebekka Wehner, PhD, Uwe Platzbecker, MD, Martin Wermke, MD, Nona Shayegi, MD, Jan Moritz Middeke, MD, Christoph Röllig, Johannes Schetelig, Gerhard Ehninger, Marc Schmitz, MD, Martin Bornhäuser, MD

Blood (2012) 120 (21): 4167.

https://doi.org/10.1182/blood.V120.21.4167.4167

Published: 2012

Journal Articles

Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation

Katja Sockel, MD, Claudia Schönefeldt, MSc, Sieghart Sopper, Martin Wermke, MD, Marc Schmitz, MD, Gerhard Ehninger, Martin Bornhäuser, MD, Dominik Wolf, MD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 4122.

https://doi.org/10.1182/blood.V120.21.4122.4122

Published: 2012

Journal Articles

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Uwe Platzbecker, MD, Friederike Braulke, Andrea Kuendgen, Katharina S. Götze, Gesine Bug, Katayoon Shirneshan, Christoph Röllig, Martin Bornhäuser, MD, Ralph Naumann, MD, Jürgen Neesen, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, Gerhard Ehninger, Prof., Ulrich Germing, MD, Detlef Haase, Martin Wermke, MD

Blood (2012) 120 (21): 921.

https://doi.org/10.1182/blood.V120.21.921.921

Published: 2012

Journal Articles

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Blood (2011) 118 (21): 255.

https://doi.org/10.1182/blood.V118.21.255.255

Published: 2011

Journal Articles

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Blood (2011) 118 (21): 247.

https://doi.org/10.1182/blood.V118.21.247.247

Published: 2011

Journal Articles

Antigen-Specific Redirection of Human Regulatory T Cells by Bispecific Antibodies,

Stefanie Koristka, Marc Cartellieri, Anke Theil, Claudia Arndt, Anja Feldmann, Irene Michalk, Marc Schmitz, Karsten Kretschmer, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Michael Bachmann

Blood (2011) 118 (21): 4041.

https://doi.org/10.1182/blood.V118.21.4041.4041

Published: 2011

Journal Articles

Redirection of Immune Effector Cells by Bispecific Antibody Systems for the Treatment of Acute Myeloid Leukemia

Claudia Arndt, Anja Feldmann, Stefanie Koristka, Irene Michalk, Marc Cartellieri, Slava Stamova, Malte von Bonin, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Michael Bachmann

Blood (2011) 118 (21): 1528.

https://doi.org/10.1182/blood.V118.21.1528.1528

Published: 2011

Journal Articles

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Christian Thiede, MD, Nona Shayegi, MD, Michael Kramer, Martin Bornhäuser, MD, Markus Schaich, MD, Johannes Schetelig, MD, Uwe Platzbecker, MD, Christoph Röllig, MD, Gerhard Ehninger, MD

Blood (2011) 118 (21): 1445.

https://doi.org/10.1182/blood.V118.21.1445.1445

Published: 2011

Journal Articles

Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute Lymphoblastic Leukemia (ALL) Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Complete Remission: Results From the GMALL Study Group.

Matthias Stelljes, MD, Mareike David, Renate Arnold, MD, Dietrich W Beelen, MD, Wolfgang A Bethge, MD, Martin Bornhäuser, MD, Jolanta Dengler, MD, Juergen Finke, MD, Hans J Kolb, MD, Karin Kolbe, MD, Nicolaus Kröger, MD, Dietger Niederwieser, MD, Wolf Rösler, MD, Rainer Schwerdtfeger, MD, Joachim Kienast, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 3352.

https://doi.org/10.1182/blood.V114.22.3352.3352

Published: 2009

Journal Articles

Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies.

Blood (2009) 114 (22): 324.

https://doi.org/10.1182/blood.V114.22.324.324

Published: 2009

NARROW

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Antigen-Specific Redirection of Human Regulatory T Cells by Bispecific Antibodies,

Redirection of Immune Effector Cells by Bispecific Antibody Systems for the Treatment of Acute Myeloid Leukemia

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only